Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates
Author:
Uzun Günalp12ORCID, Müller Rebecca3, Althaus Karina12, Becker Matthias4ORCID, Marsall Patrick4, Junker Daniel4, Nowak-Harnau Stefanie1, Schneiderhan-Marra Nicole4, Klüter Harald3, Schrezenmeier Hubert56, Bugert Peter3, Bakchoul Tamam12ORCID
Affiliation:
1. Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, 72072 Tuebingen, Germany 2. Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, 72072 Tuebingen, Germany 3. Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, 68167 Mannheim, Germany 4. NMI Natural and Medical Sciences Institute at the University of Tuebingen, 72770 Reutlingen, Germany 5. Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, 89081 Ulm, Germany 6. Institute for Transfusion Medicine and University Hospital Ulm, University of Ulm, 89081 Ulm, Germany
Abstract
COVID-19 convalescent plasma (CCP) with high neutralizing antibodies has been suggested in preventing disease progression in COVID-19. In this study, we investigated the relationship between clinical donor characteristics and neutralizing anti-SARS-CoV-2 antibodies in CCP donors. COVID-19 convalescent plasma donors were included into the study. Clinical parameters were recorded and anti-SARS-CoV-2 antibody levels (Spike Trimer, Receptor Binding Domain (RBD), S1, S2 and nucleocapsid protein) as well as ACE2 binding inhibition were measured. An ACE2 binding inhibition < 20% was defined as an inadequate neutralization capacity. Univariate and multivariable logistic regression analysis was used to detect the predictors of inadequate neutralization capacity. Ninety-one CCP donors (56 female; 61%) were analyzed. A robust correlation between all SARS-CoV-2 IgG antibodies and ACE2 binding inhibition, as well as a positive correlation between donor age, body mass index, and a negative correlation between time since symptom onset and antibody levels were found. We identified time since symptom onset, normal body mass index (BMI), and the absence of high fever as independent predictors of inadequate neutralization capacity. Gender, duration of symptoms, and number of symptoms were not associated with SARS-CoV-2 IgG antibody levels or neutralization. Neutralizing capacity was correlated with SARS-CoV-2 IgG antibodies and associated with time since symptom onset, BMI, and fever. These clinical parameters can be easily incorporated into the preselection of CCP donors.
Funder
German Research Foundation Herzstiftung Ministry of Science, Research and Art of Baden-Württemberg, Germany German Red Cross Blood Service Baden-Württemberg-Hessen
Subject
Virology,Infectious Diseases
Reference40 articles.
1. Board, G.P.M. (2020). A World in Disorder: Global Preparedness Monitoring Board Annual Report 2020. 2. Deployment of convalescent plasma for the prevention and treatment of COVID-19;Bloch;J. Clin. Investig.,2020 3. Focosi, D., Franchini, M., Pirofski, L.-A., Burnouf, T., Fairweather, D., Joyner, M.J., and Casadevall, A. (2021). COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses, 13. 4. Senefeld, J.W., Johnson, P.W., Kunze, K.L., Bloch, E.M., van Helmond, N., Golafshar, M.A., Klassen, S.A., Klompas, A.M., Sexton, M.A., and Diaz Soto, J.C. (2021). Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Med., 18. 5. Convalescent transfusion for pandemic influenza: Preparing blood banks for a new plasma product?;Leider;Transfusion,2010
|
|